Gilead Elated as the FDA OKs New Blockbuster HIV Pill Biktarvy Post author:Sam Post published:February 7, 2018 Post category:BioPharma The FDA approved Gilead’s triple combination treatment for HIV, Biktarvy. Source: BioSpace You Might Also Like Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017 Biotech Execs are Hoping Will Pick This Man to Head the FDA February 5, 2017 Bristol-Myers, Johnson & Johnson Get in on Europeon Biotech Fund's $95M Raise October 30, 2017
Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Years Of Follow-Up June 4, 2017
